Chemical Structure (7c96b52e 99c9 4b70 B467 3d00bbc58acf 01)
Clopidogrel
Product Images NDC 58118-0357
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 58118-0357). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Clinical Solutions Wholesale, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fig1 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 02)
The text describes a figure (Figure 1) that shows the exposure to a drug called Clopidogrel Active Metabolite after multiple doses of 75 mg of Clopidogrel Bisulfate alone or with different Proton Pump Inhibitors. The co-administered Proton Pump Inhibitors are: Dexlansoprazole (60 mg), Lansoprazole (30 mg), Pantoprazole (80 mg), and Omeprazole (80 mg). The figure shows the effect of these inhibitors on the active metabolite Area Under the Curve (AUC) relative to the AUC of Clopidogrel Bisulfate alone. However, no numeric data is provided in the text to determine the extent of the effect.*
Fig2 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 03)
The text describes a figure labeled as "Figure 2" which shows the occurrence of cardiovascular death, myocardial infarction, and stroke in the CURE study. The figure presents a comparison between the placebo group (treated with aspirin) and the group treated with Clopidogrel Bisulfate in combination with aspirin over a period of months of follow-up. The cumulative event rate is shown as a percentage on the vertical axis and the months of follow-up on the horizontal axis. The figure notes that other standard therapies were also used as appropriate.*
Fig3 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 04)
The text represents a table of Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study. It includes information such as patient diagnosis, age, gender, race, previous medical history, and concomitant medications/therapies. Without a clearer understanding of the study, the information may not be readily useful for all readers.*
Fig4 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 05)
The text describes cumulative event rates for death in a study called "COMMIT". The first group was given a placebo and 1845 deaths (6.1%) occurred, while the second group was given Clopidogrel and 1726 deaths (7.5%) occurred. The difference between the proportional risk before reduction was significant (p=0.03). The patients in both groups received aspirin. The graph shows the days since randomization, up to 25 days.*
Fig5 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 06)
The figure shows the cumulative event rates for the combined endpoint of re-infarction, stroke, or death in the COMMIT study. The study compared the effects of placebo versus clopidogrel on the endpoint in patients before their first discharge, up to 28 days since randomization. The results indicate that clopidogrel treatment resulted in a 9% proportional risk reduction for death and a statistically significant reduction in the combined endpoint (p = 0.002), with 2121 events (9.2%) compared to 2310 events (10.1%) in the placebo group.*
Fig6 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 07)
Fig7 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 08)
The figure shows the effects of adding Clopidogrel Bisulfate to Aspirin in Non-Prespecified Subgroups in the COMMIT study. The odds ratio and categorical data for Killip class, previous MI, and infarct location are included. The results show a proportional reduction in events for the Clopidogrel group compared to Placebo in Non-Prespecified Subgroups, with a p-value of 0.002. There is some heterogeneity in the results, but the confidence interval is within the expected range.*
Fig8 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 09)
The Figure 8 displays the cumulative event rate percentage of fatal or non-fatal vascular events over months of follow-up for Aspirin and Glopidogrel Bisulfate in the CAPRIE study. The X-axis represents the months of follow-up while the Y-axis represents the cumulative event rate percentage.*
Clopidogrel 75mg
This is a wholesale offer for Clopidogrel 75mg Tablets with a quantity of 30 and a NDC code of 58118-0357-8. The price is not available. The tablets are manufactured by Aurobindo Pharma Limited with an expiration date of September 2021. The lot number is SAMPLE123 and the batch number is SAMPLE4S6. The location of the tablets is shown as Wincso, USA, 08520 with the serial number of WMMODO00000.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
